In relation to the tumour extension (T), KRAS mutation was mostly associated with T3, as it was detected in 36 T3 tumours (66.7%), followed by T4, as it was detected in 10 T4 tumours (18.5%), and T2, as it was detected in 8 T2 tumours (14.8%). This evidence concerns the gene KRAS and neoplasm.